CN117137134A - 一种nmn辅助降脂降压的抗衰老组合物及制备方法和应用 - Google Patents
一种nmn辅助降脂降压的抗衰老组合物及制备方法和应用 Download PDFInfo
- Publication number
- CN117137134A CN117137134A CN202310635724.2A CN202310635724A CN117137134A CN 117137134 A CN117137134 A CN 117137134A CN 202310635724 A CN202310635724 A CN 202310635724A CN 117137134 A CN117137134 A CN 117137134A
- Authority
- CN
- China
- Prior art keywords
- powder
- lowering
- blood pressure
- nmn
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 210000004369 blood Anatomy 0.000 title claims abstract description 50
- 239000008280 blood Substances 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000000843 powder Substances 0.000 claims abstract description 117
- 239000000284 extract Substances 0.000 claims abstract description 66
- FZAQROFXYZPAKI-UHFFFAOYSA-N anthracene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC3=CC(S(=O)(=O)Cl)=CC=C3C=C21 FZAQROFXYZPAKI-UHFFFAOYSA-N 0.000 claims abstract description 35
- 235000013557 nattō Nutrition 0.000 claims abstract description 34
- 108010004032 Bromelains Proteins 0.000 claims abstract description 24
- 239000004365 Protease Substances 0.000 claims abstract description 24
- 235000019835 bromelain Nutrition 0.000 claims abstract description 24
- 230000036772 blood pressure Effects 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 150000002632 lipids Chemical class 0.000 claims abstract description 13
- 229940057059 monascus purpureus Drugs 0.000 claims abstract description 11
- 239000012138 yeast extract Substances 0.000 claims abstract description 11
- 229940026314 red yeast rice Drugs 0.000 claims description 16
- 244000068988 Glycine max Species 0.000 claims description 15
- 235000010469 Glycine max Nutrition 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 13
- 238000001728 nano-filtration Methods 0.000 claims description 13
- 239000000758 substrate Substances 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 240000007594 Oryza sativa Species 0.000 claims description 11
- 235000007164 Oryza sativa Nutrition 0.000 claims description 11
- 238000000855 fermentation Methods 0.000 claims description 11
- 230000004151 fermentation Effects 0.000 claims description 11
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 238000004108 freeze drying Methods 0.000 claims description 9
- 244000063299 Bacillus subtilis Species 0.000 claims description 8
- 241000228347 Monascus <ascomycete fungus> Species 0.000 claims description 8
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 7
- 238000006555 catalytic reaction Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000000108 ultra-filtration Methods 0.000 claims description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- 244000046146 Pueraria lobata Species 0.000 claims description 6
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 6
- 235000013312 flour Nutrition 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000001471 micro-filtration Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 5
- 239000004201 L-cysteine Substances 0.000 claims description 5
- 235000013878 L-cysteine Nutrition 0.000 claims description 5
- YABIFCKURFRPPO-IVOJBTPCSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxamide;chloride Chemical compound [Cl-].NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 YABIFCKURFRPPO-IVOJBTPCSA-N 0.000 claims description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims description 4
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 4
- 108010021066 nicotinamide riboside kinase Proteins 0.000 claims description 4
- 235000009566 rice Nutrition 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 244000099147 Ananas comosus Species 0.000 claims description 3
- 235000007119 Ananas comosus Nutrition 0.000 claims description 3
- 235000019270 ammonium chloride Nutrition 0.000 claims description 3
- 125000002091 cationic group Chemical group 0.000 claims description 3
- 239000013592 cell lysate Substances 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 3
- 239000003651 drinking water Substances 0.000 claims description 3
- 235000020188 drinking water Nutrition 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 3
- 235000021190 leftovers Nutrition 0.000 claims description 3
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 claims description 3
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 3
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000013049 sediment Substances 0.000 claims description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 10
- 230000036542 oxidative stress Effects 0.000 abstract description 3
- 230000009467 reduction Effects 0.000 abstract description 3
- 230000037149 energy metabolism Effects 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 description 31
- 241000700159 Rattus Species 0.000 description 19
- 230000032683 aging Effects 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 230000034994 death Effects 0.000 description 8
- 231100000517 death Toxicity 0.000 description 8
- 238000011552 rat model Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 7
- 235000007189 Oryza longistaminata Nutrition 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 230000004531 blood pressure lowering effect Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229940118019 malondialdehyde Drugs 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000035488 systolic blood pressure Effects 0.000 description 4
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 3
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 3
- 235000008696 isoflavones Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000002537 thrombolytic effect Effects 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010011356 Nucleoside phosphotransferase Proteins 0.000 description 2
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000009530 blood pressure measurement Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- 208000011897 Deaf-Blind disease Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003501 anti-edematous effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- -1 flavonoid compounds Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000010630 lipid peroxidation (MDA) assay Methods 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930185723 monacolin Natural products 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229940086319 nattokinase Drugs 0.000 description 1
- 108010073682 nattokinase Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 235000013997 pineapple juice Nutrition 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/05—Mashed or comminuted pulses or legumes; Products made therefrom
- A23L11/07—Soya beans, e.g. oil-extracted soya bean flakes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/06—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22004—Bromelain (3.4.22.4)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Botany (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Agronomy & Crop Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Cardiology (AREA)
Abstract
本发明公开了一种NMN辅助降脂降压的抗衰老组合物及其制备方法和应用。该抗衰老组合物，由以下质量百分比成分组成：β‑烟酰胺单核苷酸粉30～40％，纳豆粉10～20％，葛根提取物粉10～20％，红曲提取物粉10～20％，菠萝蛋白酶粉10～20％。本发明中各组分均为食药用原料或食用原料，具有天然安全的特点。其中，NMN可以激活机体能量代谢和改善机体氧化应激反应，配合其余组分的相互协同作用，在降压降脂增效的同时，起到良好的抗衰老作用，延长机体寿命。
Description
技术领域
本发明涉及抗衰老组合物领域。更具体地说，本发明涉及一种NMN辅助降脂降压的抗衰老组合物及其制备方法和应用。
背景技术
烟酰胺单核苷酸(Nicotinamide mononucleotide)简称NMN，分子量334.221。它是一种自然存在的生物活性核苷酸，有α和β两种不规则存在形式。β异构体是NMN的活性形式，在人体中β-NMN作为NAD+的前体，其功能通过NAD+体现。NAD+对人体健康发挥着根本性的作用，其中最为人们所知的是抗衰老方面的研究。主要表现在调节能量代谢、DNA修复和表观遗传修饰。此外，研究证明通过口服β-烟酰胺单核苷酸可增加NAD+含量，有促进血管再生、改善机体氧化应激反应和血脂水平，抑制炎症等功效。
人体衰老过程中NAD+的下降被认为是导致疾病和残疾的主要原因，如听力和视力丧失，认知和运动功能障碍，免疫缺陷，自身免疫炎症反应失调导致的关节炎、代谢障碍和心血管疾病。因此，补充β-NMN提高体内NAD+含量，能延缓、改善、防止衰老相关的多种表型，或年龄诱导的代谢紊乱、老年疾病等。
纳豆粉中的枯草杆菌纤溶酶是由枯草芽孢杆菌发酵产生的一种丝氨酸蛋白酶，具有口服溶解血栓的功效，在心血管疾病领域具有非常广阔的应用价值。
虽然现有情况中，NMN的应用在不断扩展，但是缺乏靶向作用，不能满足广大消费者对抗衰老、降脂降压、养生保健的具体要求。
发明内容
为了实现根据本发明的这些目的和其它优点，一方面，本发明的一优选实施方案提供了一种NMN辅助降脂降压的抗衰老组合物，由以下质量百分比成分组成：β-烟酰胺单核苷酸粉30～40％，纳豆粉10～20％，葛根提取物粉10～20％，红曲提取物粉10～20％，菠萝蛋白酶粉10～20％。
一优选实施方案中，所述的NMN辅助降脂降压的抗衰老组合物由以下质量百分比成分组成：β-烟酰胺单核苷酸粉35％、纳豆粉10％、葛根提取物粉15％、红曲提取物粉20％、菠萝蛋白酶粉20％。
一优选实施方案中，所述的NMN辅助降脂降压的抗衰老组合物由以下质量百分比成分组成：β-烟酰胺单核苷酸粉40％、纳豆粉15％、葛根提取物粉15％、红曲提取物粉15％、菠萝蛋白酶粉15％。
一优选实施方案中，所述β-烟酰胺单核苷酸粉由以下步骤制成：
以烟酰胺核糖氯化物为底物，将底物、腺苷三磷酸和六水氯化镁按照摩尔浓度比例70:105:50进行配制，得到底物混合物，按照质量体积比为1％～5％向底物混合物中投入烟酰胺核苷激酶或烟酰胺核苷激酶重组细胞裂解物，在pH值4.5，37℃、搅拌转速100～150rpm条件下催化反应2～3h，催化反应产物离心去除沉淀，得上清液，上清液经30nm微滤膜过滤后分别依次用20KD、1KD和200D膜进行超滤和纳滤，得纳滤液，纳滤液调pH值3.5～4.0，经阳离子树脂纯化，收获纯化液，经纳滤除盐、结晶和干燥，获得高纯度β-烟酰胺单核苷酸粉。
β-烟酰胺单核苷酸以烟酰胺核糖氯化物为底物，经过酶催化制成。它是NAD+的前体，口服β-烟酰胺单核苷酸可增加人体NAD+含量，促进糖、脂肪和氨基酸的代谢，修复DNA，参与长寿蛋白(SIRTs蛋白)合成，改善机体氧化应激反应。
一优选实施方案中，所述制备纳豆粉由以下步骤制成：
将大豆清洗干净后按质量比1:3的比例加入饮用水浸泡6～18h；浸泡后的大豆于0.02～0.05MPa、105℃蒸煮30～60min；大豆冷却至室温后按原料重量的1～10％接种枯草芽孢杆菌种子液，于温度37～41℃、湿度75～85％下发酵24～48h；发酵后的鲜纳豆放入真空冷冻干燥机进行干燥，干燥程序为-45℃进行预冻，真空度为10Pa，冷阱温度为-50℃，干燥时间为36～48h；冻干后的纳豆在粉碎机中进行粉碎、过80～100目筛，得纳豆粉。
其中，所述枯草芽孢杆菌Bacillus subtilis ZF01，菌株保藏于中国典型培养物保藏中心，保藏地点为中国武汉大学，其保藏编号为CCTCC NO:M 2022132，分类命名为Bacillus subtilis，保藏日期为2022年2月18日。
纳豆粉是用枯草芽孢杆菌发酵大豆制成，不仅保有黄豆的营养价值、富含维生素K2，更重要的是发酵过程产生了多种生物活性物质，具有溶解血栓、调节血指、血糖、血压的保健作用，如纳豆激酶、多糖、皂甙、多种氨基酸、大豆异黄酮等。因此，纳豆粉具有溶血栓、降血糖、降血压、降血脂、抗肿瘤、抗氧化等多种保健功能。
一优选实施方案中，所述制备葛根提取物粉由以下步骤制成：
取葛根原料，加入8～30倍葛根原料重量的水，80～105℃提取1～3次，每次提取时间2～6小时，提取液过滤，合并，浓缩至固形物含量5～25％，得到葛根提取浓缩液，将葛根提取浓缩液经过冷冻干燥处理，得到葛根提取物粉。
葛根的主要成分是淀粉，此外含有约12％的黄酮类化合物，包括葛根素、大豆(黄豆)甙、大豆甙元等10余种。研究表明，葛根异黄酮部分具有扩张血管和降血压的作用，常食葛根粉能调节人体机能、提高机体免疫力、延缓衰老。葛根素能扩张冠状动脉和脑血管，具有降低心肌耗氧量，改善心肌收缩，降低血压，减慢心率等功能。
一优选实施方案中，所述制备红曲提取物粉由以下步骤制成：
将红曲菌种接种发酵培养基，在24～28℃、180～200rpm下培养5～7d；所得发酵液经过滤、浓缩和冷冻干燥获得红曲提取物粉，其中所述发酵培养基中包含以下按质量分数计的组分：6～8％大米粉，1～3％大豆粉，1～2％氯化铵，0.1～0.5％磷酸氢二钾，0.1～0.5％磷酸二氢钾，0.01～0.1％硫酸镁，余量为水。
红曲是以大米为主要原料经红曲霉菌发酵而来，现代研究表明，红曲中含有莫纳可林类化合物、不饱和脂肪酸、异黄酮、生物碱等多种生物活性成分。具有降压降脂、活血化瘀、健脾消食的功效。
一优选实施方案中，所述制备菠萝蛋白酶粉由以下步骤制成：
将菠萝加工下脚料压榨的汁液进行过滤和离心，取上清液液，向上清液中加入质量体积比0.01～0.05％EDTA和质量体积比0.001～0.005％ L-半胱氨酸，搅拌均匀后微滤、超滤浓缩和冷冻干燥获得菠萝蛋白酶粉。
菠萝蛋白酶是菠萝液汁中提取的一种蛋白水解酶，常被用于抗水肿和抗炎药。口服后能加强体内纤维蛋白的水解作用，将阻塞于组织的纤维蛋白及血凝块溶解，从而改善体液的局部循环，导致炎症和水肿的消除。
另一方面，本发明的一优选实施方案提供所述的NMN辅助降脂降压的抗衰老组合物的制备方法，由以下步骤制成：
将上述质量百分比的β-烟酰胺单核苷酸粉、纳豆粉、葛根提取物粉、红曲提取物粉、菠萝蛋白酶粉按比例混合，即得所述NMN辅助降脂降压的抗衰老组合物。
另一方面，本发明的一优选实施方案提供所述的NMN辅助降脂降压的抗衰老组合物在制备降脂降压、抗衰老或者辅助降脂降压、辅助抗衰老的保健食品或药品上的应用。
本发明至少包括以下有益效果：本发明的NMN辅助降脂降压的抗衰老组合物利用食药用葛根、红曲与具有功效作用的食品纳豆粉和菠萝蛋白酶粉作为原料，具有天然、安全的特点；同时β-烟酰胺单核苷酸通过增加NAD+含量，具有促进血管再生、改善机体氧化应激反应和血脂水平、抑制炎症等功效，与天然降脂降压溶栓物质复配，充分发挥各原料在降脂降压溶栓和抗衰老方面的功效，具有良好的降脂、降压、溶栓的增效作用和抗衰老的协调促进作用。β-烟酰胺单核苷酸的制备方法采用生物酶催化反应生产，经过多重超滤、纳滤、层析柱纯化获得高纯度NMN。纳豆粉制备方法采用传统的固体发酵及冻干工艺最大限度保留了纳豆的活性成分；其他原料提取物制备方法中采用的过滤、浓缩和冷冻干燥技术具有操作简单，最大限度分离和保留了原料中活性成分。经过动物实验研究表明，本发明的NMN辅助降脂降压的抗衰老组合物能够显著改善高脂饲料喂养诱导的高血脂大鼠模型脂代谢病理状态和L-NAME诱导的高血压大鼠模型血压病理状态，并且改善衰老大鼠的寿命，降脂降压抗衰老效果显著。
本发明的其它优点、目标和特征将部分通过下面的说明体现，部分还将通过对本发明的研究和实践而为本领域的技术人员所理解。
具体实施方式
下面结合实施例对本发明做进一步的详细说明，以令本领域技术人员参照说明书文字能够据以实施。
以下描述用于揭露本发明以使本领域技术人员能够实现本发明。以下描述中的优选实施例只作为举例，本领域技术人员可以想到其他显而易见的变形。在以下描述中界定的本发明的基本原理可以应用于其他实施方案、变形方案、改进方案、等同方案以及没有背离本发明的精神和范围的其他技术方案。
实施例1
一种NMN辅助降脂降压的抗衰老组合物，含有以下质量百分比成分：β-烟酰胺单核苷酸粉35％、纳豆粉10％、葛根提取物粉15％、红曲提取物粉20％、菠萝蛋白酶粉20％。
上述组合物的制备方法，包括如下步骤：
(1)制备β-烟酰胺单核苷酸：以烟酰胺核糖氯化物为底物，将底物、腺苷三磷酸(ATP)和六水氯化镁按照摩尔浓度比例70:105:50进行配制，按照质量体积比为1％投入烟酰胺核苷激酶或烟酰胺核苷激酶重组细胞裂解物，在pH值4.5，37℃、搅拌转速120rpm条件下催化反应3h，催化反应产物离心去除沉淀，上清液经30nm微滤膜过滤后分别依次用20KD、1KD和200D膜进行超滤和纳滤，纳滤液调pH值3.5，经阳离子树脂纯化，收获纯化液经纳滤除盐、结晶和干燥获得高纯度β-烟酰胺单核苷酸粉。
(2)制备纳豆粉：将大豆清洗干净后按质量比1:3的比例加入饮用水浸泡12h；浸泡后的大豆在蒸柜中0.03MPa、105℃蒸煮30min；大豆冷却至室温后按原料重量的2％接种保藏号为CCTCC NO:M 2022132的枯草芽孢杆菌种子液，于发酵设备中发酵48h，其中发酵设备中控制温度37℃、湿度85％；发酵后的鲜纳豆放入真空冷冻干燥机进行干燥，干燥程序为-45℃进行预冻，真空度为10Pa，冷阱温度为-50℃，干燥时间为48h；冻干后的纳豆在粉碎机中进行粉碎、过80目筛，得纳豆粉。
(3)制备葛根提取物粉：取葛根原料，加入10倍重量的水，105℃提取2次，每次提取时间3小时，提取液过滤，合并，浓缩至固形物含量15％，得到葛根提取浓缩液，将葛根提取浓缩液经过冷冻干燥处理，得到葛根提取物粉；
(4)制备红曲提取物粉：将红曲菌种接种发酵培养基，8％大米粉，大豆粉2％，1％氯化铵，0.2％磷酸氢二钾，0.2％磷酸二氢钾，0.05％硫酸镁，余量为水。在25℃、200rpm下培养6d；所得发酵液经过滤、浓缩和冷冻干燥获得红曲提取物粉。
(5)制备菠萝蛋白酶粉：将菠萝加工下脚料压榨的汁液进行过滤和离心，取上清液，加入质量体积比0.02％EDTA和质量体积比0.005％ L-半胱氨酸，搅拌均匀后微滤、超滤浓缩和冷冻干燥获得菠萝蛋白酶粉，这里根据上清液的体积和EDTA、L-半胱氨酸的质量体积比，就可以计算出EDTA、L-半胱氨酸的加入量。
(6)将得到的β-烟酰胺单核苷酸粉和各个成分分别过80目筛。
(7)称量过筛后的原料，按β-烟酰胺单核苷酸粉35％、纳豆粉10％、葛根提取物粉15％、红曲提取物粉20％、菠萝蛋白酶粉20％配料，以上含量均为质量百分比含量。
(8)将配好的β-烟酰胺单核苷酸粉、纳豆粉、葛根提取物粉、红曲提取物粉、菠萝蛋白酶粉于三维混合机中混合30min，至色泽均匀一致，无色差，即得到NMN辅助降脂降压的抗衰老组合物。
实施例2
制备方法同实施例1，区别在于组合物的成分含量不同：
β-烟酰胺单核苷酸粉40％、纳豆粉15％、葛根提取物粉15％、红曲提取物粉15％、菠萝蛋白酶粉15％。
实施例3
制备方法同实施例1，区别在于组合物的成分含量不同：
β-烟酰胺单核苷酸粉30％，纳豆粉10％，葛根提取物粉10％，红曲提取物粉10％，菠萝蛋白酶粉10％。
实施例4
制备方法同实施例1，区别在于组合物的成分含量不同：
β-烟酰胺单核苷酸粉40％，纳豆粉20％，葛根提取物粉20％，红曲提取物粉20％，菠萝蛋白酶粉20％。
试验一、高血脂和抗衰老功能试验
高血脂衰老大鼠模型建立：老年大鼠喂食高脂饲料，连续4周。4周后尾静脉采血测定总胆固醇(total cholesterol，TC)水平，高脂饲料组TC水平(3.41±0.22)mmol/L显著高于正常组(1.66±0.33)mmol/L，说明模型成功。
动物分组及给药方法：选取老年大鼠，随机分7组，每组15只，第一组为正常组；第二组为模型组；第三组为红曲提取物组(其跟实施例1中的红曲提取物的加入量一致)；第四组为实施例1组；第五组为实施例2组；第六组为实施例3组；第七组为实施例4组。然后经口给予各实验组受试样品，正常组和模型组给予等体积生理盐水灌胃；各实验组受试样品每日给药剂量为1g/Kg，连续给药30d。30d后测量各组血清中TC、TG与LDL-C含量。继续给药6个月，观察各组大鼠衰老死亡情况。
结果：各组动物血清TC、TG与LDL-C的测定结果如表1所示。各组动物衰老死亡情况如表2所示。
表1各组动物血清TC、TG与LDL-C测定结果(n＝15)
注：与正常组对比，#p＜0.05，##p＜0.01。与模型组对比，*p＜0.05，**p＜0.01。
由表1可知，与模型组比较，红曲提取物组及实施例1组、实施例2组、实施例3组、实施例4组中，TC与TG、LDL-C均有下降趋势，表明红曲提取物组和本发明的NMN辅助降脂降压的抗衰老组合物都具有降血脂作用，但是相较于红曲提取物组，实施例1组和实施例2组、实施例3组、实施例4组的TC、TG、LDL-C下降幅度明显更大，也就是说，本申请的组合物的降血脂效果明显优于红曲提取物组，这是因为本申请组合物的良好的降血脂效果并不是单纯的靠其中某一种物质实现的，而是本申请中多种物质彼此协同、共同作用带来的，而且NMN辅助降脂降压的抗衰老组合物的降血脂作用优于红曲提取物组，表明各原料具有协同增效作用。
表2各组动物6个月衰老死亡结果(n＝15)
| 组别 | 死亡数量 | 存活 | 存活比例 |
| 正常组 | 2 | 13 | 86.67％ |
| 模型组 | 12 | 3 | 20.00％ |
| 红曲提取物组 | 6 | 9 | 60.00％ |
| 实施例1组 | 2 | 13 | 86.67％ |
| 实施例2组 | 3 | 12 | 80.00％ |
| 实施例3组 | 2 | 13 | 86.67％ |
| 实施例4组 | 2 | 13 | 86.67％ |
由表2可知，与模型组比较，红曲提取物组及实施例1组、实施例2组、实施例3组、实施例4组中，存活比例均有上升趋势，表明红曲提取物组和本发明的NMN辅助降脂降压的抗衰老组合物都具有抗衰老作用，但是相较于红曲提取物组，实施例1组和实施例2组、实施例3组、实施例4组的存活比例更高，也就是说，本申请的组合物的抗衰老效果明显优于红曲提取物组，这是因为本申请组合物的良好的抗衰老效果并不是单纯的靠其中某一种物质实现的，而是本申请中多种物质彼此协同、共同作用带来的，而且NMN辅助降脂降压的抗衰老组合物的抗衰老作用优于红曲提取物组，表明各原料具有协同增效作用。
试验二、高血压和抗衰老功能试验
高血压衰老大鼠模型建立：老年大鼠法腹腔注射25mg/kg/day的左旋硝基精氨酸(L-NAME)制作高血压大鼠模型，连续4周，每周采用大鼠尾容积测压法(Cuff法)测量血压一次，造模4周后测量收缩压≥140mmHg，说明模型成功。
动物分组及给药方法：选取老年大鼠，随机分7组，每组15只，第一组为正常组；第二组为模型组；第三组为葛根提取物组(其跟实施例1中的葛根提取物的加入量一致)；第四组为实施例1组；第五组为实施例2组；第六组为实施例3组；第七组为实施例4组。然后经口给予各实验组受试样品，正常组和模型组给予等体积生理盐水灌胃；各实验组受试样品每日给药剂量为1g/Kg，连续给药30d。30d后测量各组大鼠收缩压。继续给药6个月，观察各组大鼠衰老死亡情况。
结果：各组动物收缩压测定结果如表3所示。各组动物衰老死亡情况如表4所示。
表3各组动物收缩压测定结果(n＝15)
| 组别 | 造模前 | 造模4周后 | 给药30d后 |
| 正常组 | 109.13±1.88 | 112.60±2.47 | 111.13±3.18 |
| 模型组 | 108.07±1.58 | 150.87±3.93## | 151.13±2.80 |
| 葛根提取物组 | 106.20±2.01 | 146.07±2.34## | 122.13±3.78** |
| 实施例1组 | 112.53±1.68 | 152.53±2.03## | 116.87±3.58** |
| 实施例2组 | 110.07±1.58 | 148.53±3.40## | 116.67±2.94** |
| 实施例3组 | 109.07±1.02 | 150.52±4.20## | 115.63±2.44** |
| 实施例4组 | 109.85±0.85 | 151.23±3.60## | 119.45±2.53** |
注：与正常组对比，#p＜0.05，##p＜0.01。与模型组对比，*p＜0.05，**p＜0.01。
由表3可知，与模型组比较，葛根提取物组及实施例1组、实施例2组、实施例3组、实施例4组中，收缩压均有下降趋势，表明葛根提取物组和本发明的NMN辅助降脂降压的抗衰老组合物都具有降血压作用，但是相较于葛根提取物组，实施例1组和实施例2组、实施例3组、实施例4组的收缩压下降更多，也就是说，本申请的组合物的降血压效果明显优于葛根提取物组，这是因为本申请组合物的良好的降血压效果并不是单纯的靠其中某一种物质实现的，而是本申请中多种物质彼此协同、共同作用带来的，而且NMN辅助降脂降压的抗衰老组合物的降血压作用优于葛根提取物组，表明各原料具有协同增效作用。
表4各组动物6个月衰老死亡结果(n＝15)
| 组别 | 死亡数量 | 存活 | 存活比例 |
| 正常组 | 3 | 12 | 80.00％ |
| 模型组 | 13 | 2 | 13.33％ |
| 葛根提取物组 | 7 | 8 | 53.33％ |
| 实施例1组 | 1 | 14 | 93.33％ |
| 实施例2组 | 2 | 13 | 86.67％ |
| 实施例3组 | 1 | 14 | 93.33％ |
| 实施例4组 | 2 | 13 | 86.67％ |
由表4可知，与模型组比较，葛根提取物组及实施例1组、实施例2组、实施例3组、实施例4组中，存活比例均有上升趋势，表明葛根提取物组和本发明的NMN辅助降脂降压的抗衰老组合物都具有抗衰老作用，但是相较于葛根提取物组，实施例1组和实施例2组、实施例3组、实施例4组的存活比例更高，并且其存活率还高于正常组，也就是说，本申请的组合物具有很好的抗衰老效果，明显优于葛根提取物组，这是因为本申请组合物的良好的抗衰老效果并不是单纯的靠其中某一种物质实现的，而是本申请中多种物质彼此协同、共同作用带来的，而且NMN辅助降脂降压的抗衰老组合物的抗衰老作用优于葛根提取物组，表明各原料具有协同增效作用。
试验三、抗衰老试验
选取老年大鼠，随机分6组，每组15只，第一组为空白组；第二组为β-烟酰胺单核苷酸组(其跟实施例1中的β-烟酰胺单核苷酸的加入量一致)；第三组为实施例1组；第四组为实施例2组；第五组为实施例3组；第六组为实施例4组。然后经口给予各实验组受试样品，空白组给予等体积生理盐水灌胃；各实验组受试样品每日给药剂量为1g/Kg，连续给药30d。30d后测量各组血清中丙二醛(MDA)含量。结果：各组动物血清TC、TG与LDL-C的测定结果如表5所示。
表5各组动物血清MDA测定结果(n＝15)
注：与正常组对比，*p＜0.05，**p＜0.01。
由表5可知，与空白组比较，β-烟酰胺单核苷酸组及实施例1组、实施例2组、实施例3组、实施例4组中，MDA浓度均有下降趋势，表明β-烟酰胺单核苷酸组和本发明的NMN辅助降脂降压的抗衰老组合物都具有抗氧化抗衰老作用，但是相较于β-烟酰胺单核苷酸组，实施例1组和实施例2组、实施例3组、实施例4组的MDA下降更多，也就是说，本申请的组合物的抗氧化抗衰老效果明显优于β-烟酰胺单核苷酸组，这是因为本申请组合物的良好的抗衰老效果并不是单纯的靠其中某一种物质实现的，而是本申请中多种物质彼此协同、共同作用带来的，而且NMN辅助降脂降压的抗衰老组合物的抗衰老作用优于β-烟酰胺单核苷酸组，表明各原料具有协同增效作用。
通过本发明应用例可以看到，β-烟酰胺单核苷酸在改善高脂饲料喂养诱导的高血脂大鼠模型病理状态和L-NAME诱导的高血压大鼠模型血压病理状态，以及抗氧化和改善衰老大鼠的寿命有积极作用。β-烟酰胺单核苷酸粉、纳豆粉、葛根提取物粉、红曲提取物粉、菠萝蛋白酶粉搭配组合能够协同增效，显著改善诱导的高血脂大鼠模型和高血压大鼠模型病理状态，并且提高抗氧化能力和延长衰老大鼠的寿命。在降脂降压和抗衰老功能性产品开发方面具有很好的应用前景。
尽管本发明的实施方案已公开如上，但其并不仅仅限于说明书和实施方式中所列运用，它完全可以被适用于各种适合本发明的领域，对于熟悉本领域的人员而言，可容易地实现另外的修改，因此在不背离权利要求及等同范围所限定的一般概念下，本发明并不限于特定的细节和这里示出与描述的实施例。
Claims (10)
1.一种NMN辅助降脂降压的抗衰老组合物，其特征在于，由以下质量百分比成分组成：β-烟酰胺单核苷酸粉30～40％，纳豆粉10～20％，葛根提取物粉10～20％，红曲提取物粉10～20％，菠萝蛋白酶粉10～20％。
2.根据权利要求1所述的NMN辅助降脂降压的抗衰老组合物，其特征在于，由以下质量百分比成分组成：β-烟酰胺单核苷酸粉35％、纳豆粉10％、葛根提取物粉15％、红曲提取物粉20％、菠萝蛋白酶粉20％。
3.根据权利要求1所述的NMN辅助降脂降压的抗衰老组合物，其特征在于，由以下质量百分比成分组成：β-烟酰胺单核苷酸粉40％、纳豆粉15％、葛根提取物粉15％、红曲提取物粉15％、菠萝蛋白酶粉15％。
4.根据权利要求1所述的NMN辅助降脂降压的抗衰老组合物，其特征在于，所述β-烟酰胺单核苷酸粉由以下步骤制成：
以烟酰胺核糖氯化物为底物，将底物、腺苷三磷酸和六水氯化镁按照摩尔浓度比例70:105:50进行配制，得到底物混合物，按照质量体积比为1％～5％向底物混合物中投入烟酰胺核苷激酶或烟酰胺核苷激酶重组细胞裂解物，在pH值4.5，37℃、搅拌转速100～150rpm条件下催化反应2～3h，催化反应产物离心去除沉淀，得上清液，上清液经30nm微滤膜过滤后分别依次用20KD、1KD和200D膜进行超滤和纳滤，得纳滤液，纳滤液调pH值3.5～4.0，经阳离子树脂纯化，收获纯化液，经纳滤除盐、结晶和干燥，获得高纯度β-烟酰胺单核苷酸粉。
5.根据权利要求1所述的NMN辅助降脂降压的抗衰老组合物，其特征在于，所述制备纳豆粉由以下步骤制成：
将大豆清洗干净后按质量比1:3的比例加入饮用水浸泡6～18h；浸泡后的大豆于0.02～0.05MPa、105℃蒸煮30～60min；大豆冷却至室温后按原料重量的1～10％接种枯草芽孢杆菌种子液，于温度37～41℃、湿度75～85％下发酵24～48h；发酵后的鲜纳豆放入真空冷冻干燥机进行干燥，干燥程序为-45℃进行预冻，真空度为10Pa，冷阱温度为-50℃，干燥时间为36～48h；冻干后的纳豆在粉碎机中进行粉碎、过80～100目筛，得纳豆粉。
6.根据权利要求1所述的NMN辅助降脂降压的抗衰老组合物，其特征在于，所述制备葛根提取物粉由以下步骤制成：
取葛根原料，加入8～30倍葛根原料重量的水，80～105℃提取1～3次，每次提取时间2～6小时，提取液过滤，合并，浓缩至固形物含量5～25％，得到葛根提取浓缩液，将葛根提取浓缩液经过冷冻干燥处理，得到葛根提取物粉。
7.根据权利要求1所述的NMN辅助降脂降压的抗衰老组合物，其特征在于，所述制备红曲提取物粉由以下步骤制成：
将红曲菌种接种发酵培养基，在24～28℃、180～200rpm下培养5～7d；所得发酵液经过滤、浓缩和冷冻干燥获得红曲提取物粉，其中所述发酵培养基中包含以下按质量分数计的组分：6～8％大米粉，1～3％大豆粉，1～2％氯化铵，0.1～0.5％磷酸氢二钾，0.1～0.5％磷酸二氢钾，0.01～0.1％硫酸镁，余量为水。
8.根据权利要求1所述的NMN辅助降脂降压的抗衰老组合物，其特征在于，所述制备菠萝蛋白酶粉由以下步骤制成：
将菠萝加工下脚料压榨的汁液进行过滤和离心，取上清液液，向上清液中加入质量体积比0.01～0.05％EDTA和质量体积比0.001～0.005％L-半胱氨酸，搅拌均匀后微滤、超滤浓缩和冷冻干燥获得菠萝蛋白酶粉。
9.如权利要求1～8任一所述的NMN辅助降脂降压的抗衰老组合物的制备方法，其特征在于，由以下步骤制成：
将上述质量百分比的β-烟酰胺单核苷酸粉、纳豆粉、葛根提取物粉、红曲提取物粉、菠萝蛋白酶粉按比例混合，即得所述NMN辅助降脂降压的抗衰老组合物。
10.如权利要求1～8任一所述的NMN辅助降脂降压的抗衰老组合物在制备降脂降压、抗衰老或者辅助降脂降压、辅助抗衰老的保健食品或药品上的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310635724.2A CN117137134A (zh) | 2023-06-01 | 2023-06-01 | 一种nmn辅助降脂降压的抗衰老组合物及制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310635724.2A CN117137134A (zh) | 2023-06-01 | 2023-06-01 | 一种nmn辅助降脂降压的抗衰老组合物及制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117137134A true CN117137134A (zh) | 2023-12-01 |
Family
ID=88903342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310635724.2A Pending CN117137134A (zh) | 2023-06-01 | 2023-06-01 | 一种nmn辅助降脂降压的抗衰老组合物及制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117137134A (zh) |
-
2023
- 2023-06-01 CN CN202310635724.2A patent/CN117137134A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101329921B1 (ko) | 에쿠올 함유 대두 배축 발효물 및 그의 제조 방법 | |
| CN106798252B (zh) | 一种具有调理肠胃降血脂溶血栓功效的纳豆产品 | |
| CN112999261B (zh) | 一种舒缓动脉硬化的纳豆发酵组合物及其制备方法和应用 | |
| CN111568821B (zh) | 包括用冠突曲霉菌株固体发酵的发酵人参提取物的用于改善皮肤美容的组合物 | |
| KR20010072587A (ko) | 발효유로부터 유래된 골다공증 예방용의 식이성 보충식 | |
| JP7042544B2 (ja) | 脱毛治療用組成物の調製方法 | |
| CN114214366A (zh) | 一种预防和治疗贫血的小肽粉和血红素之肽红复方药物及其制备方法和应用 | |
| JP6301522B1 (ja) | 血圧上昇抑制組成物およびその製造方法 | |
| WO2019100540A1 (zh) | 一种南美白对虾饲料添加剂的制备方法 | |
| KR20160059137A (ko) | 유산균 및 천연효소를 이용한 발효삼채 제조 및 숙취해소용 혼합음료 제조방법 | |
| CN110731503A (zh) | 一种参杞蛹虫草片及其制备方法 | |
| CN111165750A (zh) | 一种利用发酵技术制备海参花粉剂的方法 | |
| CN117137134A (zh) | 一种nmn辅助降脂降压的抗衰老组合物及制备方法和应用 | |
| CN102987408B (zh) | 从蛹虫草废茧中提取游离氨基酸等营养成分的方法 | |
| CN108261539A (zh) | 一种用于抗血栓的组合物、其制备方法及用途 | |
| CN101755863A (zh) | 金银花面条及其生产方法 | |
| CN113559150A (zh) | 一种蚕蛹-桑汁复合发酵制剂的制备方法及应用 | |
| CN106260359A (zh) | 一种雪莲培养物组合物灵芝茶及其制备方法 | |
| JP5684989B2 (ja) | トゲドコロ根茎の酵素処理物及び麹菌発酵処理物 | |
| CN115153021B (zh) | 羊栖菜提取物及其在降脂降糖产品中的应用 | |
| TWI834243B (zh) | 用於生產人參皂苷的方法及其所製得的發酵產物 | |
| KR20120105972A (ko) | 홍삼 추출물과 대두 발효추출물을 포함하는 항고지혈증 및 항동맥경화 조성물 | |
| US20220273749A1 (en) | Plum extract and method for improving physical function with the same | |
| CN116602408A (zh) | 一种含有明日叶多肽的微生态提取物及其制备方法和应用 | |
| CN115057921A (zh) | 一种灰海马抗氧化抗疲劳活性胶原蛋白肽及规模化制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |